I laughed a bit when I read 'fast track' but what I think everyone needs to understand is that drug development is slow going and has to pass multiple tests/trials before commercialisation. Invions respiratory franchise is worth a lot more than the current market cap and because the drugs have established safety data and are just being reformulated/reindicated there is a larger chance of success IMO. Short term reductions in price is just another chance to accumulate.
Add to My Watchlist
What is My Watchlist?
